OptimUM-02 Subgroup Analyses in 1L HLA-A*02:01-Negative Metastatic Uveal Melanoma (PRNewswire) - Oct 19, 2026 - "In June 2026, IDEAYA reported positive results from OptimUM-02 at the American Society of Clinical Oncology (ASCO) demonstrating that 1L HLA A*02:01 -negative mUM patients treated with the darovasertib combination had a median PFS of 6.9 months by blinded independent central review (BICR) and 6.7 months by investigator assessment, compared to 3.1 months and 2.7 months in the investigator's choice of therapy (ICT) control arm, respectively. The ESMO data builds on these results, showing consistent improvements in ORR and PFS compared to ICT across multiple clinically relevant subgroups, including baseline lactate dehydrogenase (LDH) levels, ECOG performance status, largest target lesion size and choice of ICT used in the control arm. As expected, patients with higher tumor burden (lesion size ≥ 8 cm, LDH ≥ 2X ULN) had a worse prognosis, however outcomes were still better with the darovasertib combination compared to ICT."
P2/3 data • Uveal Melanoma
|